Researchers discovered a new STING agonist, CF501, and found that CF501-adjuvanted RBD-Fc vaccine elicited significantly stronger neutralizing antibody and T cell responses than Alum- and cGAMP-adjuvanted RBD-Fc in mice.
[Cell Research]
Sorry, but the selected Zotpress account can't be found.